Merus (MRUS) Cut to Sell at BidaskClub

Merus (NASDAQ:MRUS) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday, April 7th.

A number of other research analysts have also recently commented on MRUS. ValuEngine upgraded Merus from a “strong sell” rating to a “sell” rating in a research note on Monday, April 2nd. Wedbush restated an “outperform” rating and set a $32.00 price objective on shares of Merus in a research note on Friday, January 12th. Finally, Royal Bank of Canada cut Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective on the stock. in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $30.00.

How to Become a New Pot Stock Millionaire

Shares of MRUS opened at $17.68 on Friday. Merus has a 12 month low of $13.23 and a 12 month high of $23.75.

An institutional investor recently bought a new position in Merus stock. Bain Capital Public Equity Management LLC acquired a new position in shares of Merus (NASDAQ:MRUS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 196,090 shares of the biotechnology company’s stock, valued at approximately $8,297,000. Bain Capital Public Equity Management LLC owned approximately 1.01% of Merus at the end of the most recent reporting period. Institutional investors and hedge funds own 30.81% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/04/18/bidaskclub-downgrades-merus-mrus-to-sell.html.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply